Cargando…
Symptom versus exacerbation control: an evolution in GINA guidelines?
The article traces the concept of asthma control within GINA guidelines over the past 25 years. In the first 15 years after 1995, the main objective of asthma management was to obtain the control of all clinical and functional characteristics of asthma. A landmark study (GOAL) showed for the first t...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10469243/ https://www.ncbi.nlm.nih.gov/pubmed/37646243 http://dx.doi.org/10.1177/17534666231159261 |
_version_ | 1785099399897022464 |
---|---|
author | Latorre, Manuela Pistelli, Riccardo Carpagnano, Giovanna Elisiana Celi, Alessandro Puxeddu, Ilaria Scichilone, Nicola Spanevello, Antonio Canonica, Giorgio Walter Paggiaro, Pierluigi |
author_facet | Latorre, Manuela Pistelli, Riccardo Carpagnano, Giovanna Elisiana Celi, Alessandro Puxeddu, Ilaria Scichilone, Nicola Spanevello, Antonio Canonica, Giorgio Walter Paggiaro, Pierluigi |
author_sort | Latorre, Manuela |
collection | PubMed |
description | The article traces the concept of asthma control within GINA guidelines over the past 25 years. In the first 15 years after 1995, the main objective of asthma management was to obtain the control of all clinical and functional characteristics of asthma. A landmark study (GOAL) showed for the first time that a good control of asthma is a reasonable outcome that can be achieved in a large proportion of asthmatics with a regular appropriate treatment. In the following years, more emphasis was placed on the role of exacerbations as critical manifestations of poor asthma control, whose frequency is associated with excessive FEV1 decline and increased risk of death. Accordingly, the 2014 GINA report makes a clear distinction between the control of the day-by-day symptoms and the reduction in the risk of severe exacerbations, stating that both conditions should be obtained. The 2019 update included a significant change in the management of mild asthma, prioritizing the prevention of exacerbations to that of mild symptoms. This view was repeated in the 2021 update, where the prevention of exacerbations, together with an acceptable symptom control with a minimal use of rescue medication, appeared to be the real main goal of asthma management. While a discrepancy between current symptoms and exacerbations may be present in mild asthma, a significant relationship between these two features is observed in moderate-severe asthma: a persistent poor symptom control is a major risk factor for exacerbations, whereas achieving symptom control through regular treatment is associated with a reduction in exacerbation rate. Thus, the opinion that frequent symptoms are not important in the absence of acute exacerbations should be discouraged, whereas education of patients to a good symptom perception and to improve adherence to regular treatment should be implemented. Furthermore, the persistence of risk factors, such as increased airway inflammation, even in a patient with minor daily symptoms, should be considered for optimizing treatment. |
format | Online Article Text |
id | pubmed-10469243 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-104692432023-09-01 Symptom versus exacerbation control: an evolution in GINA guidelines? Latorre, Manuela Pistelli, Riccardo Carpagnano, Giovanna Elisiana Celi, Alessandro Puxeddu, Ilaria Scichilone, Nicola Spanevello, Antonio Canonica, Giorgio Walter Paggiaro, Pierluigi Ther Adv Respir Dis Review The article traces the concept of asthma control within GINA guidelines over the past 25 years. In the first 15 years after 1995, the main objective of asthma management was to obtain the control of all clinical and functional characteristics of asthma. A landmark study (GOAL) showed for the first time that a good control of asthma is a reasonable outcome that can be achieved in a large proportion of asthmatics with a regular appropriate treatment. In the following years, more emphasis was placed on the role of exacerbations as critical manifestations of poor asthma control, whose frequency is associated with excessive FEV1 decline and increased risk of death. Accordingly, the 2014 GINA report makes a clear distinction between the control of the day-by-day symptoms and the reduction in the risk of severe exacerbations, stating that both conditions should be obtained. The 2019 update included a significant change in the management of mild asthma, prioritizing the prevention of exacerbations to that of mild symptoms. This view was repeated in the 2021 update, where the prevention of exacerbations, together with an acceptable symptom control with a minimal use of rescue medication, appeared to be the real main goal of asthma management. While a discrepancy between current symptoms and exacerbations may be present in mild asthma, a significant relationship between these two features is observed in moderate-severe asthma: a persistent poor symptom control is a major risk factor for exacerbations, whereas achieving symptom control through regular treatment is associated with a reduction in exacerbation rate. Thus, the opinion that frequent symptoms are not important in the absence of acute exacerbations should be discouraged, whereas education of patients to a good symptom perception and to improve adherence to regular treatment should be implemented. Furthermore, the persistence of risk factors, such as increased airway inflammation, even in a patient with minor daily symptoms, should be considered for optimizing treatment. SAGE Publications 2023-08-30 /pmc/articles/PMC10469243/ /pubmed/37646243 http://dx.doi.org/10.1177/17534666231159261 Text en © The Author(s), 2023 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Review Latorre, Manuela Pistelli, Riccardo Carpagnano, Giovanna Elisiana Celi, Alessandro Puxeddu, Ilaria Scichilone, Nicola Spanevello, Antonio Canonica, Giorgio Walter Paggiaro, Pierluigi Symptom versus exacerbation control: an evolution in GINA guidelines? |
title | Symptom versus exacerbation control: an evolution in GINA guidelines? |
title_full | Symptom versus exacerbation control: an evolution in GINA guidelines? |
title_fullStr | Symptom versus exacerbation control: an evolution in GINA guidelines? |
title_full_unstemmed | Symptom versus exacerbation control: an evolution in GINA guidelines? |
title_short | Symptom versus exacerbation control: an evolution in GINA guidelines? |
title_sort | symptom versus exacerbation control: an evolution in gina guidelines? |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10469243/ https://www.ncbi.nlm.nih.gov/pubmed/37646243 http://dx.doi.org/10.1177/17534666231159261 |
work_keys_str_mv | AT latorremanuela symptomversusexacerbationcontrolanevolutioninginaguidelines AT pistelliriccardo symptomversusexacerbationcontrolanevolutioninginaguidelines AT carpagnanogiovannaelisiana symptomversusexacerbationcontrolanevolutioninginaguidelines AT celialessandro symptomversusexacerbationcontrolanevolutioninginaguidelines AT puxedduilaria symptomversusexacerbationcontrolanevolutioninginaguidelines AT scichilonenicola symptomversusexacerbationcontrolanevolutioninginaguidelines AT spanevelloantonio symptomversusexacerbationcontrolanevolutioninginaguidelines AT canonicagiorgiowalter symptomversusexacerbationcontrolanevolutioninginaguidelines AT paggiaropierluigi symptomversusexacerbationcontrolanevolutioninginaguidelines |